IDEXX Laboratories is rated Hold, as its premium valuation already assumes strong recurring revenue and diagnostics growth.
Hosted on MSN
Idexx raises 2025 revenue outlook to $4.28B as inVue Dx placements surge and innovation momentum builds
Jonathan J. Mazelsky, CEO, highlighted, "IDEXX delivered a very strong quarter of performance as reflected in solid execution across all key drivers of our strategy." He emphasized rapid adoption of ...
AI-powered, load-and-go platform has potential to radically shift how veterinarians process, diagnose, and act on cytology and blood morphology cases The global launch of the IDEXX (IDXX) inVue Dx ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results